Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 19/20 | 0.56 |
| ▸ | CA4 | P22748 | 7/20 | 0.56 |
| ▸ | CA1 | P00915 | 9/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA6 | P23280 | 1/20 | 0.55 |
| ▸ | CA5A | P35218 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23643754 | 0.93 | CA2 (0.59) | CA2CA4CA1CA12CA6 | |
| SCHEMBL23643367 | 0.92 | CA2 (0.62) | CA2CA4CA1CA12CA6 | |
| SCHEMBL23643580 | 0.90 | CA2 (0.45) | CA2CA4CA1CA12CA6 | |
| SCHEMBL23643586 | 0.90 | CA2 (0.58) | CA2CA4CA1CA12CA6 | |
| SCHEMBL23643659 | 0.85 | CA2 (0.55) | CA2CA4CA1CA12CA6 | |
| SCHEMBL4750255 | 0.85 | CA2 (0.68) | CA2CA4CA1CA12CA6 | |
| SCHEMBL23643697 | 0.85 | CA2 (0.61) | CA2CA4CA1CA12CA6 | |
| SCHEMBL23643723 | 0.84 | CA2 (0.47) | CA2CA4CA1CA12CA6 | |
| SCHEMBL18651252 | 0.83 | CA2 (0.67) | CA2CA4CA1CA12CA6 | |
| SCHEMBL23643610 | 0.82 | CA2 (0.68) | CA2CA4CA1CA12CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210275456-A1 | AGGREGATED MICROPARTICLES | Graybug Vision, Inc. (US) | 2021-09-09 | — | — | US | disclosed |
| US-20210214374-A1 | COMPOUNDS AND COMPOSITIONS FOR OCULAR DELIVERY | Graybug Vision, Inc. (US) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210275456-A1 | AGGREGATED MICROPARTICLES | VCL, MYOC, CD44 | CA2 1716/4885CA4 2861/4885CA1 3479/4885 |
| US-20210214374-A1 | COMPOUNDS AND COMPOSITIONS FOR OCULAR DELIVERY | KDR, RB1, PDE6C | CA2 934/4885CA4 1312/4885CA1 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.